氟哌噻吨美利曲辛片治疗伴有焦虑和(或)抑郁的咽异感症患者的疗效  

Efficacy of flupenthixol melitracen on patients with pharyngeal paraesthesia accompanied by anxiety and/or depression

作　　者：李双勇[1] 张蕾[2] 黄亮明 谢东阳[4] 曾敏波 黄文[1] 

机构地区：[1]赣南医学院第二附属医院耳鼻咽喉头颈外科,江西省赣州市341600 [2]赣南医学院第一附属医院消化内科,江西省赣州市341000 [3]江西省赣州市第三人民医院心理与睡眠科,341000 [4]赣南医学院第二附属医院心血管内科,江西省赣州市341600

出　　处：《实用医学杂志》2016年第24期4100-4104,共5页The Journal of Practical Medicine

基　　金：江西省卫生计生委科技计划课题(编号:20165390);赣南医学院校级基金资助项目(编号:YB201406)

摘　　要：目的:探讨在常规治疗基础上联合氟哌噻吨美利曲辛片(黛力新)治疗伴有焦虑和(或)抑郁的咽异感症患者的临床疗效,并观察其副反应。方法:132例伴有焦虑和(或)抑郁的咽异感症患者,按开放、随机、对照的方法分为3组:氟哌噻吨美利曲辛片联合常规治疗组(A组,43例)、盐酸氟西汀胶囊(百优解)联合常规治疗组(B组,46例)、常规治疗组(C组,43例),疗程均为4周。于入组时(0周)和治疗第1、2、4周后进行咽异感症状、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)及抗抑郁副反应量表(SERS)的评测。结果:共完成了120例患者的研究(A组40例、B组41例、C组39例)。治疗4周后,在咽异感症状和HAMA、HAMD评分的总有效率方面,A、B两组均优于C组,差异均有统计学意义(均P<0.001),但A、B两组差异无统计学意义。A、B、C组的咽异感症状、HAMA评分、HAMD评分的总有效率分别为:A组87.50%(35/40)、85.00%(34/40)、87.50%(35/40);B组78.05%(32/41)、82.93%(34/41)、90.24%(37/41);C组48.72%(19/39)、46.15%(18/39)、38.46%(15/39)。A组患者HAMA和HAMD评分在治疗2周后见明显改善,而B组在4周后才见明显改善。SERS评定中,两组均未见明显不良反应。结论:氟哌噻吨美利曲辛片联合常规治疗对伴有焦虑和(或)抑郁的咽异感症患者疗效显著,副反应极少,且较目前临床上常用的盐酸氟西汀胶囊显效时间早,值得临床推广应用。Objective To evaluate the efficacy and adverse effects of flupentixol melitracen combined with conventional therapy in the treatment of patients with pharyngeal paraesthesia accompanied by anxiety and/ or depression. Methods The clinical trial was a open, randomized, controlled study. Totally 132 cases with pharyngeal paraesthesiawere divided into Deanxit combined with conventional therapy group （group A, 43 cases）, PROZAC combined with conventional therapy group （group B, 46 cases） and conventional therapy group （group C, 43 cases） for a four-week treatment course. The patients were evaluated by the severity of pharyngeal paraesthesia, the Hamilton anxiety scale （HAMA）, the Hamilton depression rating scale （HAMD） and the rating scale for side effects （SERS） when enrolled and were followed up at the 1st , 2nd and 4th week. The efficacy was evaluated by the total efficacy rate. Results A total of 120 patients completed the trial, including 40 patients in group A, 41 patients in group B and 39 patients in group C. After four-week treatment, the total efficacy rate of pharyngeal paraesthesia and HAMA/HAMD scoring in group A and B were higher than those in group C, and the difference was statistically significant （all P 〈 0.001）, but there was no statistical difference in terms of total efficiency rate between group A and B. The total efficacy rate of three groups in pharyngeal paraesthesia, HAMA and HAMD was 87.50% （35/40）, 85.00% （34/40）, and 87.50% （35/40） ; 78.05% （32/41）, 82.93% （34/41）, and 90.24%（37/41）; 48.72%（19/39）, 46.15%（18/39） and 38.46%（15/39） respectively. HAMA/HAMD score was improved obviously in group A after two weeks of treatment but in group B, the obvious improvement was observerd after four weeks of treatment. No obvious adverse effects were found in both group A and B. Conclusions Flupentixol melitraeen combined with conventional therapy for the treatment of pharyngeal paraesthesia accompanied by anxiety and/or depression is effe

关 键 词：咽异感症 抑郁 焦虑 氟哌噻吨 美利曲辛 

分 类 号：R749[医药卫生—神经病学与精神病学] R76[医药卫生—临床医学]